Rachel King

Track

Insider profile

Currently holds positions in Novavax, Inc. and Crescent Biopharma, Inc.

Performance

Overall performance
2.3
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 13% 8.2% 15.1%
Success rate 75% 68% 82%
Transactions
5 80% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return -15%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Novavax, Inc. Nov. 1, 2018 -
President, Chief Executive Officer, Co-Founder, Director Crescent Biopharma, Inc. Jan. 1, 2003 -
Rachel King's trades of Novavax, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US Novavax, Inc. (NVAX)
Transaction date
Sale
Price
394.76
Quantity 29,934 -5.7%
Value US$1,614,262
US Novavax, Inc. (NVAX)
Transaction date
Proposed sale
Price
239.64
Quantity 13,310
Value US$4,308,516
US Novavax, Inc. (NVAX)
Transaction date
Purchase
Price
352.96
Quantity 13,689 +3.6%
Value US$4,447,351
US Novavax, Inc. (NVAX)
Transaction date
Purchase
Price
0.53
Quantity 22,000 +inf%
Value US$11,656
US Novavax, Inc. (NVAX)
Transaction date
Purchase
Price
0.53
Quantity 22,000 +inf%
Value US$11,656
US Novavax, Inc. (NVAX)
Transaction date
Purchase
Price
0.53
Quantity 42,000 +inf%
Value US$22,252
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-02 2024-12-13
US Novavax, Inc. (NVAX)
S Sale
29,934 -5.7%
394.76
US$1,614,262 		29,934 -5.7% 394.76 US$1,614,262
2024-12-13 2024-12-13
US Novavax, Inc. (NVAX)
PrS Proposed sale
13,310
239.64
US$4,308,516 		13,310 239.64 US$4,308,516
2021-05-21 2021-05-19
US Novavax, Inc. (NVAX)
B Purchase
13,689 +3.6%
352.96
US$4,447,351 		13,689 +3.6% 352.96 US$4,447,351
2020-12-30 2020-12-28
PlS Planned sale
84,176 -19.1%
3.91
US$329,128 		84,176 -19.1% 3.91 US$329,128
2019-03-28 2019-03-27
US Novavax, Inc. (NVAX)
B Purchase
22,000 +inf%
0.53
US$11,656 		22,000 +inf% 0.53 US$11,656
2019-03-28 2019-03-27
US Novavax, Inc. (NVAX)
B Purchase
22,000 +inf%
0.53
US$11,656 		22,000 +inf% 0.53 US$11,656
2019-03-28 2019-03-27
US Novavax, Inc. (NVAX)
B Purchase
42,000 +inf%
0.53
US$22,252 		42,000 +inf% 0.53 US$22,252